A phase I study of Ad-RTS-mIL-12 + veledimex in pediatric brain tumors, including diffuse intrinsic pontine glioma (DIPG)
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Brain cancer; Glioma
- Focus Adverse reactions
- 16 Oct 2017 According to a ZIOPHARM Oncology media release, this study is being conducted at leading pediatric cancer centers across the United States, including Ann & Robert H. Lurie Childrens Hospital in Chicago, Dana-Farber Cancer Institute in Boston and the University of California, San Francisco.
- 16 Oct 2017 According to a ZIOPHARM Oncology media release, first patient has been dosed.
- 16 Oct 2017 Status changed from planning to recruiting, according to a ZIOPHARM Oncology media release.